THETHE LIMIT FOR THE COMPLAINT’S NOTIFICATION IS NOVEMBER 21, 2022

NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP announces that it has filed a federal securities class action lawsuit against Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) on behalf of a class of all natural persons in the United States District Court for the Central District of California and entities that purchased Fulgent’s publicly traded securities between March 22, 2019 and August 4, 2022, both dates inclusive (the “Collection Period”).

All investors who own Fulgent Genetics, Inc. and any losses incurred are advised to contact the company immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You can get additional information about the promotion or join the case on our website, www.whafh.com.

If you’ve suffered losses at Fulgent Genetics, Inc., you can at the latest November 21, 2022, request that the court appoint you lead plaintiff in the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in Fulgent Genetics, Inc.

PLEASE CLICK HERE TO JOIN THE EVENT

Fulgent, along with its subsidiaries, provides COVID-19, molecular diagnostics and genetic testing services to physicians and patients in the United States and internationally. As a result, Fulgent must comply with the federal anti-kickback statute, which prohibits knowingly and intentionally paying funds “Compensation” to induce or reward patient referrals or the generation of business involving items or services to be paid for by federal healthcare programs, and the Stark federal law prohibiting a physician from making referrals for certain designated healthcare services, including laboratory services, through the Medicare program to an entity with which the physician or immediate family member has a direct or indirect financial relationship.

On August 4, 2022, Fulgent will…